LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Lista de Ações・Pacific Biosciences of California Inc

Pacific Biosciences of California Inc

Fechado

SetorSaúde

1.28 -5.19

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.28

Máximo

1.35

Indicadores-chave
By Trading Economics
Rendimento	32M -8.3M
Vendas	-7.5M 37M
EPS	-0.12
Margem de lucro	-22.258
Funcionários	485
EBITDA	509K -38M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+75% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-60M 421M
Abertura anterior	6.47
Fecho anterior	1.28

Sentimento de Notícias

By Acuity

15%

85%

312 / 346 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

1.13 / N/A Suporte e Resistência

Pacific Biosciences of California Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

12 de mai. de 2026, 22:50 UTC

Ganhos

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 de mai. de 2026, 22:49 UTC

Ganhos

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 de mai. de 2026, 22:32 UTC

Ganhos

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 de mai. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 de mai. de 2026, 22:57 UTC

Conversa de Mercado

Ganhos

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 de mai. de 2026, 22:26 UTC

Ganhos

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 de mai. de 2026, 22:25 UTC

Ganhos

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 de mai. de 2026, 22:25 UTC

Ganhos

Aristocrat Leisure Interim Dividend A$0.50/Security

12 de mai. de 2026, 22:24 UTC

Ganhos

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 de mai. de 2026, 22:23 UTC

Ganhos

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 de mai. de 2026, 22:23 UTC

Ganhos

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 de mai. de 2026, 22:19 UTC

Ganhos

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 de mai. de 2026, 22:14 UTC

Ganhos

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 de mai. de 2026, 22:14 UTC

Ganhos

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 de mai. de 2026, 22:13 UTC

Ganhos

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 de mai. de 2026, 22:12 UTC

Ganhos

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 de mai. de 2026, 22:12 UTC

Ganhos

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 de mai. de 2026, 22:11 UTC

Ganhos

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 de mai. de 2026, 22:11 UTC

Ganhos

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 de mai. de 2026, 22:10 UTC

Ganhos

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 de mai. de 2026, 22:09 UTC

Ganhos

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 de mai. de 2026, 22:09 UTC

Ganhos

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 de mai. de 2026, 22:08 UTC

Ganhos

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 de mai. de 2026, 22:07 UTC

Ganhos

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 de mai. de 2026, 22:06 UTC

Ganhos

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 de mai. de 2026, 22:06 UTC

Ganhos

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 de mai. de 2026, 22:05 UTC

Ganhos

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 de mai. de 2026, 22:04 UTC

Ganhos

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 de mai. de 2026, 22:04 UTC

Ganhos

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 de mai. de 2026, 22:04 UTC

Ganhos

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Comparação entre Pares

Variação de preço

Pacific Biosciences of California Inc Previsão

Preço-alvo

By TipRanks

75% parte superior

Previsão para 12 meses

Média 2.38 USD 75%

Máximo 3 USD

Mínimo 1.5 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Pacific Biosciences of California Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

4 ratings

Comprar

Manter

Vender

Com base em 4 analistas que deram avaliações de ações para Pacific Biosciences of California Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

1.13 / N/ASuporte e Resistência

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Sentimento

By Acuity

312 / 346 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.